Search Results

New Medicare coverage guidelines include AmnioBand® Membrane and AlloPatch® Pliable, aseptically processed allografts, among 17 covered tissues  Edison, N.J. (November 21, 2024) —  MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts and advancing the science of tissue transplantation, today announced two of its aseptically processed allografts, AmnioBand® Membrane, an allograft placental matrix, and AlloPatch® Pliable, an allograft dermis matrix, are among the select few tissues to remain covered under the new Medicare medical coverage guidelines. These new guidelines are based on published clinical evidence and reduced the number of covered tissues from over 200 to 17, reaffirming MTF Biologics’ commitment to providing clinically proven solutions for wound care.  Under the new Medicare guidelines, AmnioBand® Membrane and AlloPatch® Pliable are both covered for the treatment of diabetic foot ulcers, offering providers a choice between a placental and dermal allograft solution. AmnioBand® Membrane will be one of only five tissues covered for the treatment of venous leg ulcers. These new guidelines align with the medical coverage policies of the majority of commercial health plans, ensuring broad market applicability for both new and existing distribution partners. They also guarantee that healthcare providers and the Medicare beneficiaries that they treat, who suffer from these recalcitrant wounds, continue to have access to these safe, effective, and economically advantageous tissue forms.   “Medicare’s new guidelines reflect the importance of clinical evidence and quality in wound care solutions,” said Joe Yaccarino, President & Chief Executive Officer of MTF Biologics. “Our inclusion on this exclusive list of covered tissues highlights our ability to deliver trusted tissues that meet the needs of clinicians and patients alike. We are excited to continue to support our distribution partners in delivering a broad range of exceptional, clinically proven solutions to the wound care market.”    MTF Biologics AmnioBand® Membrane and AlloPatch® Pliable key features include:  Aseptically Processed : Utilizes aseptic processing methods, rather than terminal irradiation, to preserve tissue integrity and quality.  Dual-Tissue Offering : The only organization on the Medicare list to provide both an allograft dermis matrix (AlloPatch® Pliable) and an allograft placental matrix (AmnioBand® Membrane).  Proven Clinical Results : Peer-reviewed Level 1 clinical evidence shows these tissues nearly double healing rates compared to standard of care, achieving closure with an average of four applications.  Cost-Effectiveness : Published studies demonstrate that these high-quality tissues offer some of the lowest cost-to-closure rates and superior outcomes​.1,2,3​    About MTF Biologics  MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists.    The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.   For more information about our  wound care portfolio , visit  https://www.centuriontherapeutics.com/ .   About Centurion Therapeutics  Centurion Therapeutics is a leading distributor of medical products, dedicated to improving patient care through innovative solutions and exceptional service. With a focus on delivering cutting-edge technologies to healthcare professionals, Centurion Therapeutics is committed to advancing the field of medicine and enhancing patient outcomes.   Contact  Aleksa Loch Email:  aleksa.loch@finnpartners.com     Plast Reconstr Surg Glob Open. 2016 Oct 12:4(10):e1095. eCollection 2016.  Int Wound J. 2016 Apr 12 doi: 10.1111/iwj.12600 [Epub ahead of print]  MTF data on file

Centurion Therapeutics is proud to announce a strategic partnership with Pensar Medical, a leader in negative pressure wound therapy (NPWT). This collaboration will focus on distributing the Microdoc® sNPWT (single-use negative pressure wound therapy) platform, a cutting-edge solution designed to enhance patient care and provide advanced wound management across a wide range of healthcare settings. The Microdoc® sNPWT system represents a breakthrough in wound care, offering a cost-effective and efficient method for treating both chronic and acute wounds. By combining Pensar Medical's innovative technology with our extensive distribution network, we aim to promote the widespread adoption of the Microdoc® platform. This partnership allows us to leverage our network of over 500 sales professionals operating in more than 600 sites of care, bringing the benefits of sNPWT to more patients than ever before. "The addition of the Microdoc® sNPWT system to our product lineup aligns perfectly with our mission to provide comprehensive wound and surgical management solutions nationwide," said Robert Goodwin, President and CEO of Centurion Therapeutics. "We are thrilled to offer this innovative product to our distribution partners and their customers." The market for single-use negative pressure wound therapy is rapidly expanding, with an estimated annual growth rate of over 20%. Research has demonstrated that sNPWT can significantly reduce surgical site infections, which currently cost the U.S. healthcare system more than $3.3 billion annually. Devices like Microdoc® have been shown to potentially reduce this risk by more than 50%, underscoring the importance of expanding access to such technologies. "We are excited to partner with Centurion Therapeutics," said Jason Bandy, CEO of Pensar Medical. "Their strong presence in the inpatient market, combined with our NPWT technology, will enable us to reach more patients and improve outcomes." This collaboration marks an important step forward in our commitment to advancing wound care and improving patient outcomes. We look forward to working closely with Pensar Medical to make a meaningful impact in the field of wound management. For more details on this partnership, please read the full press release here . For information about Microdoc® visit our website here .

Organizations build on existing relationship, forging new agreement aimed at growing distribution of wound care innovations in acute care and post-acute care settings Centurion Therapeutics, Exclusive World Wide Partner of MTF Biologics Edison, NJ, June 13, 2024 – MTF Biologics , a global leader in tissue-based solutions, and Centurion Therapeutics , a pioneering distributor in the medical field, today announced they have entered into a new agreement that will give more clinicians and patients in complex wound settings within hospitals and post-acute care facilities access to advanced wound healing technologies. The agreement, which is an expansion of a five-year collaboration between MTF Biologics and Centurion, grants Centurion exclusive distribution rights for a range of MTF Biologics’ tissue technologies, including placental, dermal, and adipose tissues. The tissue forms covered in the agreement include Amnioband® Membrane , Salera® Membrane , Salera® Mini-Membrane , Allopatch® Pliable , Allopatch® Meshed , Somagen® Meshed Dermal Matrix , and Leneva® Adipose Matrix . The agreement also includes provisions for ongoing training, marketing, and support to ensure effective promotion and distribution of the tissue forms.     “We are thrilled to announce this expanded partnership with Centurion Therapeutics,” said Joe Yaccarino, President & Chief Executive Officer of MTF Biologics. “Its team has proven their expertise over the past five years with us and demonstrated their reach within complex surgical wound care. The company is the ideal partner to help us deliver our innovative tissue solutions to healthcare professionals and, ultimately, save and heal more lives. We have had a long and successful history with Centurion’s team in representing MTF Biologics’ technologies and look forward to our continued success.”     MTF Biologics and Centurion Therapeutics Partner. Centurion Therapeutics will play a vital role in expanding the reach of MTF Biologics’ tissue forms to key customers, including surgical podiatrists, orthopedic surgeons, spine surgeons, vascular surgeons, OB/GYN surgeons, and general surgeons.     “We are honored to collaborate with MTF Biologics to bring their extraordinary tissue technologies to the forefront of medical practice,” said Robert Goodwin, President and Chief Executive Officer at Centurion Therapeutics. “This partnership and expanded relationship represent a significant step forward in our mission to provide healthcare professionals with the tools they need to improve outcomes in patients suffering complex wounds.”     The agreement underscores both companies’ commitment to excellence in patient care and innovation in the complex surgical wound management within the acute and post-acute care setting.   For more information about MTF Biologics and its tissue forms, visit www.mtfbiologics.org . For more information about Centurion Therapeutics and its distribution services, visit www.centuriontherapeutics.com .     About Centurion Therapeutics  Centurion Therapeutics is a leading distributor of medical products, dedicated to improving patient care through innovative solutions and exceptional service. With a focus on delivering cutting-edge technologies to healthcare professionals, Centurion Therapeutics is committed to advancing the field of medicine and enhancing patient outcomes. Visit www.centuriontherapeutics.com  for more information.  About MTF Biologics MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.     The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals they serve. Its sister organization, Deutsches Institute for Zell-und   Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. For more information, visit www.mtfbiologics.org .     Contact: Aleksa Loch, aleksa.loch@finnpartners.com   June 13, 2024

Join Centurion Therapeutics at SAWC Fall 2024 in Las Vegas! We are thrilled to announce that Centurion Therapeutics will be attending the Symposium on Advanced Wound Care (SAWC) Fall 2024 Conference! This premier event, organized by HMP Global, will take place from October 2-5 in the vibrant city of Las Vegas, Nevada. We invite you to join us for an enriching experience that promises to advance your knowledge and expertise in wound care. About SAWC Fall 2024 The SAWC Fall Conference is the leading event in the field of wound care, bringing together healthcare professionals, researchers, and industry leaders from around the globe. The conference offers an extensive program featuring: Cutting-Edge Research:  Presentations on the latest advancements in wound care. Expert Speakers:  Insights from renowned experts in the field. Interactive Workshops:  Hands-on sessions to enhance practical skills. Networking Opportunities:  Connect with peers, leaders, and innovators. Why Attend? Attending SAWC Fall 2024 is an unparalleled opportunity to: Stay Informed:  Learn about the latest trends, treatments, and technologies in wound care. Expand Your Network:  Build connections with other professionals and industry leaders. Enhance Your Skills:  Participate in workshops and sessions designed to improve your clinical practice. Explore Innovations:  Discover new products and services that can enhance patient care. Let Us Know You're Coming! We would love to connect with you at the conference. Let us know you're coming, and we can set up a meeting to go over our solutions with you! For more information about our company and portfolio, please visit our website: Centurion Therapeutics . Centurion Therapeutics Solutions At Centurion Therapeutics, we offer a range of innovative technologies for soft tissue repair, including: MTF Biologics Wound Care Tissues: AmnioBand® Membrane:  An allograft membrane serving as a scaffold for replacing damaged or inadequate tissue. Leneva®:  The first-of-its-kind allograft matrix using human adipose tissue for soft tissue reconstruction. SomaGen® Meshed:   an acellular human reticular dermal allograft with a unique meshed design that provides a scaffold to support the treatment of a variety of complex wounds. AlloPatch® Pliable and AlloPatch Meshed:   an acellular human reticular dermal allograft that provides the f ramework to support cellular repopulation and vascularization in wound beds. Salera® Membrane:  Designed to optimize surgical outcomes and reduce complications in poorly healing patients. Salera® Mini Membrane: Designed to align with your goal of optimizing surgical outcomes and reducing complications in poor-healing patients. Pensar Medical Negative Pressure Wound Therapy : MicroDoc® : A Patient Friendly, Single-Use Pressure Wound Therapy Device Save the Date! Mark your calendars for October 2-5 and make plans to join us in Las Vegas for SAWC Fall 2024. Stay tuned for more updates and information on our participation at the conference. How to Register and Join Us at SAWC Fall 2024 Visit the SAWC Fall 2024 website  to learn more about the conference and register for the event. Don't miss this chance to be part of the leading wound care conference of the year! We look forward to seeing you there! For any inquiries or further information, please contact us at Support@CenturionTherapeutics.com or (760) 518-6482. Stay connected with us on our website  or LinkedIn  for the latest updates and news. #SAWCFall2024 #WoundCare #MedicalDistribution #SaveTheDate #JoinUsInVegas

CMS Announces Proposed Coverage for Skin Substitute Grafts On April 25, 2024, the Medicare Administrative Contractors (MACs) released a proposed Local Coverage Determination (LCD) aimed at providing appropriate coverage for skin substitute grafts used in the treatment of chronic non-healing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). This collaborative effort, titled "Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers," ensures that Medicare beneficiaries have access to skin substitute products supported by evidence as reasonable and necessary for treating these conditions, aligning with professional guidelines for effective wound management. Call for Public Comments on Coverage Determination for Skin Substitute Grafts CMS encourages all interested parties to participate in the LCD process by providing comments during the public comment period, which remains open until June 8, 2024. Each MAC will host public listening sessions throughout May, offering additional opportunities for stakeholder engagement on this proposed coverage policy. CMS Commitment to Access and Engagement CMS prioritizes ensuring that Medicare beneficiaries have access to clinically appropriate items and services. The organization will closely monitor the LCD process to guarantee meaningful engagement opportunities. How to Participate The LCD process is open to all interested parties wishing to submit comments on the proposed determination. To participate: Submit comments by June 8, 2024, via your MAC’s website. Attend an Open Meeting where the proposed LCD will be discussed. Registration details are available on your MAC’s website or the CMS Landing Page at CMS LCD Process . If unable to attend an Open Meeting, recordings will be posted on each MAC’s website. For more information, visit the CMS LCD Process . Press Release Details Date: April 25, 2024Source: CMS News and Media GroupContact: Catherine Howden, DirectorMedia Inquiries: 202-690-6145